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Should we screen for the sexually-
transmitted infection Mycoplasma 
genitalium? Evidence synthesis 
using a transmission-dynamic 
model
Ruthie Birger  1,2, John Saunders3,4, Claudia Estcourt3,4,5, Andrew John Sutton6,7, Catherine 
H. Mercer8, Tracy Roberts9 & Peter J. White  1,10,11
There is increasing concern about Mycoplasma genitalium as a cause of urethritis, cervicitis, pelvic 
inflammatory disease (PID), infertility and ectopic pregnancy. Commercial nucleic acid amplification 
tests (NAATs) are becoming available, and their use in screening for M. genitalium has been advocated, 
but M. genitalium’s natural history is poorly-understood, making screening’s effectiveness unclear. 
We used a transmission-dynamic compartmental model to synthesise evidence from surveillance data 
and epidemiological and behavioural studies to better understand M. genitalium’s natural history, and 
then examined the effects of implementing NAAT testing. Introducing NAAT testing initially increases 
diagnoses, by finding a larger proportion of infections; subsequently the diagnosis rate falls, due to 
reduced incidence. Testing only symptomatic patients finds relatively little infection in women, as a 
large proportion is asymptomatic. Testing both symptomatic and asymptomatic patients has a much 
larger impact and reduces cumulative PID incidence in women due to M. genitalium by 31.1% (95% 
range:13.0%-52.0%) over 20 years. However, there is important uncertainty in M. genitalium’s natural 
history parameters, leading to uncertainty in the absolute reduction in PID and sequelae. Empirical 
work is required to improve understanding of key aspects of M. genitalium’s natural history before it will 
be possible to determine the effectiveness of screening.
There is increasing concern about the sexually-transmitted bacterium, Mycoplasma genitalium, as a cause of a 
range of morbidities1,2 including mucopurulent cervicitis1,3–6, pelvic inflammatory disease (PID)1,5–11, tubal fac-
tor infertility1,12,13, and ectopic pregnancy in women7–10,12–18; urethritis, balanitis, posthitis and balanoposthitis 
in men19–21; and increased HIV acquisition and transmission22. An increasing array of commercial nucleic acid 
amplification tests (NAATs) are available, for example, the Bio-Rad Dx CT/NG/MG® assay23, many of which 
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are non-invasive (urine-based), and using them to screen for M. genitalium has been advocated24, and this may 
reduce the incidence of serious, costly sequelae in women25.
However, there is uncertainty in its importance as a cause of disease, whether public health intervention is 
justified and, if so, how best to intervene14,25–27. Uncertainty in the natural history of M. genitalium needs to 
be accounted for in analyses of the likely impact of screening26. Extensive screening for Chlamydia trachomatis 
has been implemented by several countries – for more than a decade in England, and yet the impact of this 
screening is still poorly-understood28. In large part this is because natural history of C. trachomatis is still not 
well-understood, reflected by wide variation in the values of key parameters used in mathematical models29; only 
in recent years has evidence synthesis been used to improve estimates30,31.
As highlighted by Walker et al. “transmission dynamics and duration of infection [are] both important factors 
in understanding the management of [M. genitalium] in the population”14. We used a transmission-dynamic 
model to synthesise evidence32 from studies of the natural history and epidemiology of M. genitalium, and sur-
veillance data, to identify the parameters that are most important in contributing to uncertainty in its transmis-
sion dynamics. We then examined the potential impact of using NAATs for (i) diagnostic testing of symptomatic 
patients, and (ii) diagnostic testing of symptomatic patients plus screening of asymptomatic patients, of both 
sexes, on incidence of infection and diagnoses in each sex and incidence of serious sequelae in women.
Methods
Model structure. We developed a transmission-dynamic compartmental mathematical model in which M. 
genitalium’s epidemiology is represented by compartments for asymptomatic infected individuals, symptomatic 
infected individuals not seeking treatment, symptomatic infected individuals seeking treatment, and women with 
asymptomatic, symptomatic and treated PID33. The model is stratified by sex, and into ‘activity classes’ with low, 
medium, and high rates of sexual partner change. Interaction between activity classes is determined by a mix-
ing matrix, with an assortativeness coefficient specifying the amount of like-with-like interaction34. The model 
is summarised by the flow diagram in Fig. 1; equations specifying the model are in the Appendix. Acquisition 
of infection causes individuals to move from the Susceptible state to the Latent state, from which they progress 
to one of the Infectious states. Infectious individuals may be Asymptomatic, Symptomatic but not seeking care 
despite their symptoms, or Symptomatic and seeking care. Individuals may seek care following partner notifica-
tion: this applies to persons with and without infection and with and without symptoms. When an infected indi-
vidual is diagnosed and treated successfully, they return to the Susceptible state. If treatment is unsuccessful, then 
the patient enters the Treatment Failure state; those individuals then seek further treatment due to continuing 
symptoms (this time treated successfully) or recover through natural immune processes. Infected individuals who 
do not receive treatment will recover eventually through natural immune processes, returning to the Susceptible 
state. If an Asymptomatic individual is treated and treatment fails, then they remain in the Asymptomatic infected 
state, and recover naturally – unless partner notification leads to their being diagnosed and treated again. In 
women, a proportion of cases of untreated infection and of treatment failure cases will progress to PID. A propor-
tion of PID cases are symptomatic and seek care due, entering the Treated PID state, with successful treatment 
returning them to the Susceptible state. All cases of PID can recover through natural immune processes and 
Figure 1. Model flow diagram illustrating schematically the natural history of M. genitalium infection 
and the care-seeking behaviour of infected individuals. Compartments represent mutually exclusive states 
of individuals, and arrows indicate the direction of flow between compartments. Susceptible individuals 
are uninfected. All other compartments contain infected individuals, all of whom are infectious except for 
those with latent infection. Upon progression from latent infection, all individuals have signs of disease 
and symptomatic individuals also have symptoms. Some individuals with symptoms seek care due to their 
symptoms; others do not. Arrows showing return to the uninfected Susceptible state indicate both natural 
recovery and treatment. The model population is stratified into males and females and into classes with low, 
medium, and high rates of sexual partner change (not shown). Only females can experience PID.
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return to the Susceptible state. Numbers of cases of ectopic pregnancy and tubal factor infertility were calculated 
by multiplying the number of untreated PID cases by the proportions of PID cases developing each sequela as 
reported in previous studies15–17,30.
We used surveillance data from England, where all symptomatic men and 5% of asymptomatic men attending 
sexual health clinics received screening for non-chlamydial non-gonococcal urethritis (NCNGU) with urethral 
gram stain microscopy35 and diagnosed cases were recorded. In general practice, microscopy is not used at all and 
people are managed according to symptoms. Women with symptoms of mucopurulent cervicitis would be treated 
(and the diagnosis recorded in surveillance), whilst asymptomatic women with infection would only be treated 
(and recorded in surveillance) through partner notification.
Symptomatic cases of NCNGU were given first-line treatment with azithromycin; a proportion of these cases 
(estimates are described below) will have been due to M. genitalium, and a proportion of those will have been 
cured by it. M. genitalium can be treated with azithromycin, doxycycline and cefoxitin, with treatment failure 
rates ranging from 5–60%9,36–39. Moxifloxacin is more effective but is often reserved as a second-line treatment38.
Sensitivity analysis to identify the most epidemiologically important parameters. To identify 
which parameters have the greatest impact on the model output (i.e. diagnoses in men and prevalence in women), 
prior ranges for parameters values were defined, based on literature and expert opinion (Table 1)8,9,36,40–44. Some 
parameter estimates were well-defined, including sexual partner change rates45; time-delays associated with seek-
ing and receiving care46,47; the proportion of symptomatic patients abstaining from sexual activity whilst seeking 
care46–48; and the effectiveness of treatment41,49. Natural history parameters of M. genitalium were more uncertain, 
due to variation between studies of estimates or due to a lack of studies. These include the transmission proba-
bility; the proportion of infections that are symptomatic; the latent period and duration of infection; and the rate 
of progression to PID. In the univariate analysis, the model was run using intermediate values of all the ranges of 
the parameters while allowing one parameter at a time to vary between the minimum and maximum of the range. 
The most influential parameters were then varied in the model calibration step.
Model calibration. The model represents the UK population aged 18–40 years, with 10 million individuals 
of each sex. Since testing for M. genitalium is not routine, we use surveillance data on diagnoses of NCNGU 
in men from sexual health clinics in the UK in 2000–200950, complemented by estimates of the proportion of 
NCNGU that is due to M. genitalium (i.e. 10–46%19,20,51,52). In men in the UK, there were ~65,000 annual diag-
noses of urethritis due to NCNGU, ~10% of which were asymptomatic epidemiologically-treated cases50. The 
model was calibrated to estimated numbers of annual M. genitalium diagnoses in men (including asymptomatic 
epidemiologically-treated cases), and the prevalence in women (i.e. 3.3% (95% CI: 2.6–4.1%))11. Candidate 
parameter sets were generated by Latin Hypercube Sampling from the prior ranges of parameters that were 
uncertain and influential. Parameter sets were accepted if both the annual diagnoses and prevalence fell within 
the specified ranges defined by the data: the female prevalence generated by the model had to fall in the range 
2.6–4.1%, and the annual number of male diagnoses had to fall between 6,500–29,900 (i.e.10–46% of 65,000 
Figure 2. Comparison of model prevalence and diagnoses to data. Panels contain histograms showing the 
distributions of the prevalence in females and annual diagnoses in males produced by the sets of accepted 
parameter values from the calibration process.
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Description Symbol
Prior range Posterior range
SourceLow Mean High Low Mean High
Rate of aging in and out (per year) μ 1/22 22-yr age range
Proportion of population in low risk 
activity class plow 0.56 55,64
Proportion of population in medium 
risk activity class pmed 0.3 55,64
Proportion of population in high risk 
activity class phigh 0.14 55,64
Partner change rate in low risk activity 
class (per year) rlow 0.15 55,64
Partner change rate in medium risk 
activity class (per year) rmed 0.76 55,64
Partner change rate in high risk activity 
class (per year) rhigh 8.49 55,64
Sex-act frequency (per 4 weeks) q 7 65
Sexual mixing assortativeness 
coefficient ε 0.1 0.5 0.9 0.1 0.42 0.9 EO
Per-sex act transmission probability: 
male to female φ(f) 0.01 0.155 0.3 0.07 0.18 0.30 3,61,66–68
Per-sex act transmission probability: 
female to male φ(m) 0.01 0.155 0.3 0.08 0.23 0.3 3,61,66–68
Latent period (days) dlat 14 19
Proportion of incident infections that is 
symptomatic: female z(f) 0.01 0.355 0.7 0.09 0.38 0.7 3,13,69,70
Proportion of incident infections that is 
symptomatic: male z(m) 0.1 0.4 0.7 0.1 0.2 0.57 3,13,69,70
Proportion of symptomatic infecteds 
who seek care spontaneously: female ρ(f) 0.01 0.6 0.9 0.01 0.26 0.87 EO
Proportion of symptomatic infecteds 
who seek care spontaneously: male ρ(m) 0.6 0.795 0.99 0.6 0.77 0.99 EO
Time from symptom onset to seeking 
care (days) dseek 0 10 20 0.05 9.46 19.76 46,47
Time from seeking care to obtaining 
it (days) dcare 7 46
Proportion of infecteds seeking care 
abstaining from sex: female α(f) 0.2 0.4 0.6 0.2 0.4 0.6 46–48
Proportion of infecteds seeking care 
abstaining from sex: male α(m) 0.4 0.6 0.8 0.4 0.59 0.8 46–48
Per-capita rate of sexual-health 
screening in those without symptoms 
(per day)
σ(f) 0.24 EO
Per-capita rate of sexual-health 
screening in those without symptoms, 
male (per day)
σ(m) 0.001 0.089 0.138 0.005 0.076 0.132 71
Proportion of patients who go directly 
to GUM pGUMD 0.3 0.5 0.7 0.303 0.47 0.7 72
Proportion of patients who go to GUM 
from GP pGPGUM 0.1 0.25 0.4 0.103 0.24 0.4 42
Proportion of men without symptoms 
who are screened by microscopy at 
GUM
η 0.05 35
Specificity of microscopy specm 97% 73
Sensitivity of microscopy sensm 80% 73
Specificity of NAAT test specp 96% 74
Sensitivity of NAAT test sensp 87% 74
Partner notification look-back period 
(days) dlook 60 75
Proportion of partners traced from 
index patients diagnosed in GUM fGUM 0.01 0.55 0.7 0.03 0.28 0.6 50,76
Proportion of partners traced from 
index patients diagnosed in GP fGP 0.01 0.255 0.5 0.01 0.19 0.5 42,43
Mean delay in treatment of contacts 
(days) τ 10 EO
Treatment failure proportion (without 
NAAT testing) ζ 0.05 0.351 0.6 0.05 0.28 0.596 9,36,38,39,41
Treatment failure proportion (second-
line without NAAT testing; first line 
with NAAT testing)
ζ — 0.05 — — — — 2,27
Continued
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NCNGU diagnoses). The parameter-selection process was run until 200 accepted parameter sets were obtained 
(from ~40,000 candidate sets), which comprise the posterior distribution. Sensitivity analysis was then performed 
to determine the most influential parameters, by calculating partial rank correlation coefficients (PRCCs)53.
After selection of parameter sets to represent uncertainty in transmission dynamics, the model was used to 
examine the impact of NAAT testing of (i) symptomatic individuals of both sexes in both genitourinary medicine 
(GUM) and general practice (GP) clinics (plus the 5% of asymptomatic patients in GUM who were being tested 
by microscopy because those clinics would be unlikely to stop testing that patient group), and (ii) all symptomatic 
patients of both sexes in both GUM and GP clinics plus asymptomatic patients attending GUM. In addition to 
higher diagnosis rates, it was assumed that NAAT testing would allow for more effective treatment, so that treat-
ment failure rates would be lower. In scenario analysis, we varied the progression rate parameter, ψ, using values 
of 0.022, 0.044, and 0.09, which correspond to percentages of M. genitalium infections in women progressing to 
PID of 2.1%, 4.5%, and 8.5%6,11.
Model code (available on request) was implemented using Matlab version 2016b.
Results
Model sensitivity analysis and calibration. The model was able to reproduce the observed epidemi-
ological data (diagnosis rates in men and prevalence in women). In the univariate sensitivity analysis that was 
performed to determine which parameters would be varied in the model calibration step, the most influential 
parameters associated with uncertainty in the model output were proportion of infections that are symptomatic; 
proportion of symptomatics abstaining from sex; the proportion of those patients who seek care; time from onset 
to care-seeking; per-capita rate of care-seeking; proportion of patients who go to GUM, directly or via GP; sex-
ual mixing pattern (assortativeness coefficient); transmission probabilities; proportion of partners traced; treat-
ment failure rate; and natural recovery rates. (Table 1, parameters with prior and posterior ranges, Tables 2, 3 for 
post-fitting PRCC calculations as described below).
For parameters that were varied in probabilistic sampling, the prior ranges are reported in Table 1, with the 
distribution of model prevalence in females and annual diagnoses in males amongst the posterior parameter sets 
shown in Fig. 2. Posterior parameter distributions are reported in Table 1 and plotted in Fig. 3. For some of the 
parameters, the prior and posterior ranges and mean values were similar (Fig. 3), indicating that the priors were 
in agreement with the other available data that we synthesised, but also that those data provided only limited 
additional information on these parameter values, indicated by the limited reduction in the range of uncertainty. 
For other parameters, related to sexual behaviour (ε, σ(m)), natural history of infection (φ(f), φ(m), z(f), z(m), 
γ(f), γ(m)), use of and performance of the health service (ρ(f), dseek, fGUM, fGP), and the treatment failure propor-
tion (ζ), prior and posterior mean values were different, indicating that the surveillance data were informative, 
although in most cases the prior and posterior ranges were similar.
There is uncertainty in the baseline number of PID cases due to M. genitalium, with estimates of 155,700 (95% 
range 69,000–273,000), 306,000 (134,000–545,000), and 605,000 (256,000–1,120,000) over 20 years, correspond-
ing to proportions of untreated infections in women progressing to PID of 2.1%, 4.5%, and 8.5%, respectively 
(Table 4 and Supplementary Tables 1 & 2), which are generated by using ψ values of 0.022, 0.044, and 0.09, 
respectively. Price et al.30 estimated the incidence of all-cause PID to be 1.8% p.a., which equates to 192,000 cases 
annually in a population of the size used in the model, and corresponds to 3,843,000 cases over 20 years. This 
means that the proportion of all-cause PID that is estimated to be due to M. genitalium is 4.1%, 8.0%, or 15.7%, 
Description Symbol
Prior range Posterior range
SourceLow Mean High Low Mean High
Natural recovery rate: female (per year) γ(f) 0.3 1.2 2.4 0.46 1.23 2.37 8,11,38,60,62
Natural recovery rate: male (per year) γ(m) 0.3 0.65 1 0.3 0.6 0.955 11,38,62
Natural recovery rate following 
treatment failure (per year) γF 2 EO
Duration of treatment-failed infection 
before retreatment (months) dinf2 1 EO
Natural recovery rate from PID (per 
year) γPID 0.25 EO
Rate of progression to PID – calibration 
(per day) ψP 0.022 11
Rate of progression to PID – scenario 
analysis (per day) ψP 0.022, 0.044, 0.09 6,11
Proportion of those with PID seeking 
treatment y 0.5 EO
Mean duration of PID before treatment 
(days) dPT 40 EO
PID treatment duration (days) dtp 21 EO
Proportion of PID cases developing 
tubal factor infertility pTFI 0.08 15–17,30
Proportion of PID cases developing 
ectopic pregnancy pEP 0.12 15–17,30
Table 1. Model parameters. Parameters which were sampled have prior and posterior ranges reported; other 
parameter values were fixed. “EO” denotes expert opinion. Adapted from Estcourt et al. 2016.
www.nature.com/scientificreports/
6SCIENTIfIC REpoRtS | 7: 16162  | DOI:10.1038/s41598-017-16302-8
corresponding to proportions of untreated infections in women progressing to PID of 2.1%, 4.5%, and 8.5%, 
respectively. For comparison, Price et al.30 estimated that 14.8% of chlamydia infections progress to PID, and that 
19.7% of all-cause PID is due to chlamydia.
Impact of NAAT testing. Introduction of NAAT testing leads to an increase in diagnosis and treatment, 
leading to a reduction in the incidence of infection, which declines over a sustained period, with uncertainty in 
natural history and behaviour parameters leading to uncertainty in the magnitude of the reduction (Figs 4 and 5). 
The impact on PID of NAAT testing is marked (Fig. 5, Table 4), particularly in the scenario where asymptomatic 
patients are screened because this identifies many more of the infections that occur compared with only testing 
Annual reports of symptomatic males diagnosed in GUM Female prevalence Annual reports of epidemiologically-treated males
Parameter Description
Parameter 
Name PRCC Parameter Description
Parameter 
Name PRCC Parameter Description
Parameter 
Name PRCC
Proportion Symptomatic (M) z(m) 0.73** Proportion Care-seeking (F) ρ f( ) −0.28* Proportion Care-seeking (F) f( )ρ 0.74**
Transmission Probability 
(F→M) f( )φ 0.54** Recovery rate (F) f( )γ −0.20* Assortativeness Coefficient  0.65**
Proportion of patients who go 
straight to GUM pGUMD 0.49** Assortativeness Coefficient  −0.18* Proportion Symptomatic (F) z(f) 0.64**
Proportion Care-seeking (M) m( )ρ 0.43** Proportion Symptomatic (M) z(m) −0.17* Proportion of patients who go straight to GUM pGUMD 0.33**
Proportion Care-seeking (F) ρ f( ) −0.22* Transmission Probability (M→F) φ m( ) 0.15*
Proportion of patients who go to 
GUM from GP pGPGUM 0.21*
Proportion of patients who go 
to GUM from GP pGPGUM 0.17** Proportion Symptomatic (F) z(f) −0.14*
Transmission Probability 
(F→M) f( )φ 0.16*
Assortativeness Coefficient  −0.15* Recovery rate (M) γ m( ) −0.11 Recovery rate (F) γ f( ) 0.15*
Recovery rate (F) f( )γ −0.14* Proportion Care-seeking (M) m( )ρ −0.10 Transmission Probability (M→F) φ m( ) 0.13
Proportion Symptomatic (F) z(f) −0.13 Proportion of patients who go straight to GUM pGUMD −0.09
Reduction in sexual activity 
when care-seeking (F) α(f) −0.08
Transmission Probability 
(M→F) φ m( ) 0.11
Proportion of patients who go 
to GUM from GP pGPGUM −0.07 Recovery rate (M) γ m( ) −0.06
**p <0.001, *p<0.05
Table 2. Sensitivity of model to values of sampled parameters. The table presents partial rank correlation 
coefficients (PRCCs) for the varied parameters with respect to annual numbers of symptomatic males 
diagnosed in GUM, prevalence in females, and annual numbers of epidemiologically-treated males. In each 
case, parameters are ranked by their importance, with statistically-significant effects indicated. In the Parameter 
Description columns, “(F)” and “(M)” refer to female and males, respectively.
Female Incidence Reduction Male Incidence Reduction PID Prevalence Reduction
Parameter Description
Parameter 
Name PRCC Parameter Description
Parameter 
Name PRCC Parameter Description
Parameter 
Name PRCC
Care-seeking rate of 
Asymptomatic Males σ(m) 0.67**
Care-seeking rate of 
Asymptomatic Males σ(m) 0.60**
Care-seeking rate of 
Asymptomatic Males σ(m) 0.67**
Proportion Symptomatic (F) z(f) −0.51** Proportion Symptomatic (F) z(f) −0.51** Proportion Symptomatic (F) z(f) −0.58**
Transmission Probability 
(M→F) φ m( ) −0.38**
Transmission Probability 
(F→M) φ f( ) −0.38** Recovery rate (F) γ f( ) −0.35**
Assortativeness Coefficient  0.34** Assortativeness Coefficient  0.36** Transmission Probability (F→M) f( )φ −0.32**
Recovery rate (F) γ f( ) −0.29** Recovery rate (F) f( )γ −0.32** Assortativeness Coefficient  0.30**
Proportion of patients who go 
to GUM from GP pGPGUM 0.16* Proportion Care-seeking (F) ρ f( ) 0.16* Proportion Care-seeking (F) f( )ρ 0.17*
Proportion Care-seeking (F) f( )ρ 0.14 Proportion of patients who go straight to GUM pGUMD 0.14
Proportion of patients who go 
to GUM from GP pGPGUM 0.16*
Proportion of patients who go 
straight to GUM pGUMD 0.13
Proportion of patients who go 
to GUM from GP pGPGUM 0.13
Proportion of patients who go 
straight to GUM pGUMD 0.15*
Proportion Care-seeking (M) m( )ρ 0.09 Proportion Care-seeking (M) m( )ρ 0.09 Proportion Symptomatic (M) z m( ) −0.07
**p <0.001, *p<0.05
Table 3. Sensitivity of model to values of sampled parameters. The table presents partial rank correlation 
coefficients (PRCCs) for the varied parameters with respect to annual numbers of reductions in female and 
male incidence and PID prevalence. In each case, parameters are ranked by their importance, with statistically-
significant effects indicated. In the Parameter Description column, “(F)” and “(M)” refer to female and male, 
respectively.
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symptomatic patients. NAAT testing enables detection of infection in women as well as men, detection of asymp-
tomatic infection, and improved care of symptomatic patients because M. genitalium is treated specifically, rather 
than syndromic management being given for NCNGU/mucopurulent cervicitis.
Whereas introducing NAAT testing results in an immediate reduction in incidence which increases over time 
in both sexes, the effect on the rate of diagnoses is different. Initially there is an increase in diagnoses, due to 
the increase in testing, followed by a decline in diagnoses, due to the consequent reduction in prevalence and 
incidence of infection. The long-term effect on the diagnosis rate depends upon the testing scenario and differs 
for each sex. When NAAT testing is used for symptomatic patients (Figs 4a and 5a), the diagnosis rate in women 
increases by a relatively small amount and in the long-term falls below the baseline diagnosis rate prior to the 
intervention, whereas in men the initial increase in the diagnosis rate is proportionately larger, and in the long 
term, the diagnosis rate remains above baseline. When NAAT testing is used for symptomatic patients and asymp-
tomatic patients in GUM (Figs 4b and 5b), the diagnosis rate in women increases by a relatively large amount 
and in the long-term remains slightly above the baseline diagnosis rate, whereas in men the initial increase in the 
diagnosis rate is proportionately smaller, and in the long term, the diagnosis rate remains slightly below baseline. 
The scenario presented in Figs (4b and 5b) is perhaps the one more likely to occur in practice, with the advent of 
multiplex NAAT tests meaning that asymptomatic patients tested for C. trachomatis and/or N. gonorrhoeae will 
often be tested automatically for M. genitalium as well.
Whilst in all cases NAAT testing reduced the incidence of M. genitalium infection and reduced the incidence 
of PID and other sequelae, it is important to note that uncertainty in M. genitalium’s natural history parameters 
leads to substantial uncertainty in the magnitude of these changes. In the case of the rate of diagnosis of M. genita-
lium infection there was uncertainty not only in the magnitude of the change but also in whether in the long term 
the diagnosis rate would be higher or lower (and it could be different for each sex). We calculated PRCCs for each 
parameter with respect to symptomatic male cases, epidemiologically treated male cases, and female prevalence, 
as well as for reductions in female and male incidence and PID prevalence (Tables 2, 3). The most influential 
Figure 3. Comparison of prior and posterior parameter values. For sampled parameters, the prior and 
posterior distributions (min, mean, max) are shown: the prior distributions are on the left of each pair. 
Prior distributions were all uniform, except where triangular, as indicated on the relevant plots. Posterior 
distributions are shown as violin plots, with red crosses representing the mean values, and green boxes 
representing the medians. Parameters are as follows: φ(f), φ(m): Per-sex act transmission probability (male to 
female, male to female, respectively); ε: Sexual mixing assortativeness coefficient; γ(f), γ(m): Natural recovery 
rate (female, male, respectively); z(f), z(m): Proportion of incident infections that is symptomatic (female, male, 
respectively); ρ(f), ρ(m): Proportion of symptomatic infecteds who seek care spontaneously (female, male, 
respectively); fGUM: Proportion of partners traced from index patients diagnosed in GUM; fGP: Proportion of 
partners traced from index patients diagnosed in GP; pGUMD: Proportion of patients who go directly to GUM; 
pGPGUM: Proportion of patients who go to GUM from GP; α(f), α(m): Proportion of infecteds seeking care who 
abstain from sex (female, male, respectively); dseek, Time from symptom onset to seeking care; ζ, Treatment 
failure proportion (first-line treatment); σ(m), Per-capita rate of sexual-health screening in those without 
symptoms (male).
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parameters for each were rate of asymptomatic males seeking care, proportion of females who are symptomatic 
and female to male transmission probability. This analysis indicates that getting better estimates for these param-
eters will be key for maximally accurate assessment of the impact of NAAT testing roll-out.
Discussion
We find that screening for M. genitalium using NAATs could lead to significant reductions in rates of PID in 
women due to M. genitalium, with cumulative incidence over 20 years reduced by 31.1% (95% range: 13.0–52.0%). 
This will reduce incidence of other serious sequelae arising from PID such as ectopic pregnancy and tubal factor 
infertility. Using NAAT testing for M. genitalium in general practice/community and specialist settings, instead 
of urethral smear microscopy testing of symptomatic men in GUM and syndromic management of both sexes, 
greatly reduces the incidence of infection and PID, particularly when symptomatic and asymptomatic patients 
are tested. This is for several reasons. Firstly, coverage of testing can be greater, as it can be offered to more patients 
(in community settings as well as GUM), and will likely be more acceptable to men than urethral smear micros-
copy. Secondly, women can be tested by NAAT, meaning that treatment of infection in women is not dependent 
upon either having symptomatic infection or being a notified partner of a man diagnosed with infection. Thirdly, 
detecting infection in women then enables contact tracing to find their male partners, further-reducing infec-
tion in the population. Moreover, with antibiotic resistance in M. genitalium causing increasing concern2,27,54, an 
important benefit of NAAT diagnosis of M. genitalium infection rather than syndromic management of NCNGU 
is that it allows use of a more-appropriate treatment regimen; NAATs can detect genetic determinants of drug 
resistance.
Importantly, our modelling shows that patterns observed in rates of diagnosis differ from patterns in under-
lying incidence, which needs to be taken into account when assessing surveillance data, as has previously been 
highlighted for gonorrhoea55: specifically, incidence falls immediately and remains lower than prior to interven-
tion, whilst the diagnosis rate initially increases and then falls, and in the long-term the diagnosis rate may be 
lower or higher than prior to the intervention. A diagnosis rate that remains elevated may be interpreted wrongly 
as indicating a failure of the intervention or even a higher incidence of infection than prior to intervention.
To our knowledge, we are the first to use a transmission-dynamic model to synthesise evidence on the natural 
history and epidemiology of M. genitalium, and the impact of screening and treatment. We have identified key 
natural history parameters whose values are uncertain, which leads to considerable uncertainty in the magnitude 
of the effect of screening. Further research is required to obtain better estimates of these parameters before it 
can be determined how effective NAAT-based screening for M. genitalium is likely to be. Natural history studies 
of sexually-transmitted infections typically concentrate on women, due to concern about serious sequelae, but 
since most infected women become infected from men it is important to know parameter values for both sexes, 
to inform effective control policies. We note that results are not always as expected: in the case of C. trachomatis, 
established infections clear more slowly in men than women, which is the opposite of what is typically assumed31.
Our analysis shows that particularly important for M. genitalium transmission are the proportion of infections 
that are symptomatic (and proportion of those that are treated), duration of untreated infection, and infectivity, in 
Cumulative 
incidence Mean
Weighted 
mean Median 95% range
Difference from baseline
Mean 95% range
Pelvic Inflammatory Disease
Baseline 309,000 306,000 293,000 134,000–545,000 — —
NAAT testing 
for symptomatic 
patients
275,000 272,000 259,000 125,000–519,000 33,800 ~0–87,800
NAAT testing for 
all patients 219,000 216,000 205,000 75,900–458,000 89,600 40,400–150,000
Tubal Factor Infertility
Baseline 18,500 18,400 17,600 8,000–32,700 — —
NAAT testing 
for symptomatic 
patients
16,500 16,300 15,500 7,500–31,100 2,000 ~0–5,300
NAAT testing for 
all patients 13,100 13,000 12,300 4,600–27,500 5,400 2,400–9,000
Ectopic Pregnancy
Baseline 12,400 12,300 11,700 5,400–21,800 — —
NAAT testing 
for symptomatic 
patients
11,000 10,900 10,300 5,000–20,800 1,400 ~0–3,500
NAAT testing for 
all patients 8,800 8,600 8,200 3,000–18,300 3,600 1,600–6,000
Table 4. Numbers of cases of serious sequelae in women due to M. genitalium in the different scenarios, over 
20 years. In the scenarios presented here 4.5% of infections progress to PID. Weighted mean figures are averages 
of results obtained using the accepted parameter sets, weighted by the likelihood of each parameter set. The 
Difference columns report the difference between the baseline and intervention scenarios, calculated using the 
likelihood-weighted mean estimates, and the 95% ranges of the differences.
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both sexes. Measurement of these parameters will involve a variety of studies56, including analysis of surveillance 
data; it is possible to calculate population prevalence of infection based on rates of screening and diagnosis57. To 
maximise the value of surveillance data it is important to have a good understanding of the processes that lead to 
patients being tested and diagnosed to be able to make more-precise inferences57, e.g. what proportion of diag-
nosed infections are in symptomatic vs asymptomatic individuals, and what is each patient’s reason for testing, 
Figure 4. Effect of NAAT testing on incidence and prevalence of M. genitalium infection and rates of diagnosis. 
(a) NAAT testing of symptomatic men and symptomatic women in GP and GUM clinics, and of the 5% of 
asymptomatic men who were previously were screened in GUM with microscopy; (b) NAAT testing for all 
patients in GUM clinics plus symptomatic patients in GP clinics. Box plots show the mean, interquartile range, 
95% range and outliers of the proportionate change in rates compared with baseline for each of the accepted 
parameter sets. Year 0 is the baseline. Note that in each scenario, (a) and (b), the vertical scales for changes 
in incidence are the same for both sexes but are different for changes in diagnoses. In both sexes, there is a 
reduction in incidence of infection, with incidence declining over time. The rate of diagnoses shows a different 
pattern from incidence: there is initially an increase, due to the increase in testing, followed by a decline, due to 
the consequent reduction in incidence and prevalence of infection. The patterns of changes in rates of diagnosis 
are different for each sex and differ between testing scenarios.
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e.g. due to symptoms, being a notified partner of a diagnosed case, having been at perceived risk of infection and 
sought a test, or having been offered screening by a healthcare provider.
Combining data from contact tracing with whole-genome sequencing of isolates allows estimation of the tim-
ing of transmission from person to person, which provides lower-bound information on the duration of infection; 
this has been done for gonorrhoea and could be applied to M. genitalium58. Estimates of the duration of untreated 
infection are best obtained from cohort studies in which individuals are followed over months or years without 
infections being treated, which have been performed for M. genitalium in women11,59 (see Smieszek & White 
201660 for a synthesis of those studies) but not men. Such studies are only possible where testing for and treating 
M. genitalium is not the standard of care. It is therefore vital to conduct studies urgently before screening and 
treating M. genitalium becomes common due to adoption of multiplex NAAT testing.
Multiplex NAATs that test for both C. trachomatis and M. genitalium provide an opportunity for large-scale 
surveillance, of M. genitalium, at minimal cost, through unlinked anonymous testing for M. genitalium of sam-
ples from patients who are screened for C. trachomatis, in order to identify risk groups in whom screening for 
M. genitalium would be justified. Additionally, diagnosis of NCNGU requires ruling-out of C. trachomatis and 
N. gonorrhoeae, so using a multiplex test that detects those organisms plus M. genitalium would be a simple way 
to monitor the proportion of NCNGU that is associated with M. genitalium and examine associations with age, 
sex, and location. Such studies are important since the positive predictive value (PPV) of the test depends upon 
the prevalence of infection in those screened, as well as test sensitivity and specificity, and only in groups where 
Figure 5. Impact on serious sequelae in women of introducing NAAT testing for M. genitalium. (a) NAAT 
testing symptomatic men and women in GP and GUM clinics, and NAAT testing of the 5% of asymptomatic 
men who were previously screened in GUM with microscopy; (b) NAAT testing of all patients in GUM clinics 
and symptomatic patients in GP clinics; Year 0 is the baseline. There is uncertainty in the magnitude of the effect 
due to uncertainty in natural history and behaviour parameter values, so results are presented as frequency 
distributions of proportionate changes in rates of PID due to M. genitalium. It takes at least several years for the 
full effect of the change to occur.
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prevalence is sufficiently high is the PPV high enough to justify screening for treatment. It might be appropriate 
to target M. genitalium testing by age, or according to patient characteristics (e.g. those with symptoms, and/or 
with greater numbers of recent sexual partners)11,61–63. Geographic targeting may be appropriate, since it is likely 
that prevalence will vary geographically, as it does for C. trachomatis57.
In conclusion, it is unclear at present whether screening for M. genitalium should be recommended, due to 
uncertainty in key natural history parameters identified in our analysis. The ongoing uncertainty in the impact 
of chlamydia screening highlights the need for caution. We hope that this work will enable empirical research 
activity to be focused where it will be most effective in informing public-health decision-making.
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